Latest news with #RothCapital
Yahoo
21 hours ago
- Business
- Yahoo
Roth Capital Lowers Antero Resources (AR) PT to $44 Due to Weaker Natural Gas Prices
Antero Resources Corporation (NYSE:AR) is one of the best upside stocks to invest in now. On July 31, Roth Capital analyst Leo Mariani lowered the firm's price target on Antero Resources to $44 from $45, while maintaining a Buy rating on the shares. The firm increased earnings estimates after the company's Q2 2025 earnings report but trimmed the price target to reflect weaker natural gas prices. Antero Resources reported an average net production of 3.4 Bcfe/d, consisting of 2.2 Bcf/d of natural gas and 200 MBbl/d of liquids in Q2. The realized pre-hedge natural gas equivalent price was $3.85 per Mcfe, which was a $0.41 premium to NYMEX. However, the company's realized natural gas price was negatively impacted by a $0.05 per Mcf discount to the benchmark index, caused by maintenance on a Gulf Coast pipeline in June. A fleet of tanker trucks transporting oil and natural gas, amidst the backdrop of open fields. Antero Resources achieved strong financial results, with a net income of $157 million and an adjusted net income of $110 million. The company generated $262 million in free cash flow, which it used to reduce its net debt by $187 million to a total of $1.1 billion. Additionally, Antero purchased 3.6 million shares for ~$126 million between April 1 and July 30. Antero Resources Corporation (NYSE:AR) is an independent oil and natural gas company that develops, produces, explores, and acquires natural gas, natural gas liquids/NGLs, and oil properties in the US. While we acknowledge the potential of AR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Roth Capital Raises Bloom Energy Corporation (BE)'s Price Target
Bloom Energy Corporation (NYSE:BE) is among the 11 Best Hydrogen Stocks to Invest in Now. Roth Capital increased its price target for Bloom Energy Corporation (NYSE:BE) from $25 to $34 on August 1 while keeping its rating at Neutral following the firm's Q2 earnings beat. According to analyst Chip Moore, the firm's patented solid oxide technology platform and its capacity to quickly implement solutions in regions with growing grid constraints have allowed it to dominate the hydrogen fuel cell market. A crowded drilling platform in the Western Canada Sedimentary Basin, the workers handling oil and natural gas equipment. Bloom Energy Corporation (NYSE:BE) is positioned as an important player in the energy transformation, providing customers with scalable, sustainable power solutions. Roth Capital's view shows faith in its proven technology and its long-term ability to assist in decarbonization initiatives. Based on Moore's statement, Bloom Energy Corporation (NYSE:BE)'s solid oxide platform is strategically relevant as energy infrastructure experiences increasing strain since it can be used for both stationary power generation and integration into changing hydrogen ecosystems. The revised target comes after stronger-than-expected quarterly results, even though Roth Capital's Neutral attitude reflects a balanced assessment of valuation at present share levels. It is among the Best Hydrogen Stocks. While we acknowledge the potential of BE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Business Insider
3 days ago
- Business
- Business Insider
Gain Therapeutics price target lowered to $6 from $7 at Roth Capital
Roth Capital lowered the firm's price target on Gain Therapeutics (GANX) to $6 from $7 and keeps a Buy rating on the shares after meeting with its CEO to discuss the company's Phase 1b study evaluating lead candidate GT-02287 in Parkinson's disease. The CSF biomarker data expected in Q4 makes most sense 'to gain preliminary conviction' as it better capitulates pathological changes associated with iPD and GBA1-PD vs. serum biomarker analysis, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
09-08-2025
- Business
- Business Insider
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301
After Cingulate (CING) announced the termination of Laurie Myers as COO, Roth Capital caught up with Cingulate Therapeutics' CEO Shane Schaffer to get additional clarity on the 'sudden termination.' The firm's conversation with the CEO suggests the COO's departure has no meaningful impact on the company's near-term strategy or long-term outlook, including the timelines for CTx-1301 FDA approval expected in mid-2026. Following the talks with the CEO, the firm reiterates its Buy rating and $11 price target on Cingulate shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
08-08-2025
- Business
- Business Insider
OptimizeRx price target raised to $27 from $22 at Roth Capital
Roth Capital raised the firm's price target on OptimizeRx (OPRX) to $27 from $22 and keeps a Buy rating on the shares after its 'very strong' Q2 results. The firm cites the company's revenues and adjusted EBITDA both sharply above forecasts. OptimizeRx is well positioned for accelerated growth in 2025 and beyond, an outlook that is still at odds with its still-muted 2025 revenue growth guidance of 13%-17%, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
